About Natera (NASDAQ:NTRA)
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).
Industry, Sector and Symbol
Industry MEDICAL CARE
Trailing P/E Ratio-3.66153846153846
Forward P/E Ratio-5.09
Sales & Book Value
Annual Sales$210.94 million
Price / Sales2.44
Price / CashN/A
Book Value($0.19) per share
Price / Book-50.11
Return on Equity-357.12%
Return on Assets-71.89%
Natera (NASDAQ:NTRA) Frequently Asked Questions
What is Natera's stock symbol?
Natera trades on the NASDAQ under the ticker symbol "NTRA."
How were Natera's earnings last quarter?
Natera Inc (NASDAQ:NTRA) posted its quarterly earnings results on Wednesday, November, 8th. The medical research company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.04. The medical research company had revenue of $56.66 million for the quarter, compared to analyst estimates of $55.31 million. Natera had a negative net margin of 64.61% and a negative return on equity of 357.12%. The firm's quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.50) earnings per share. View Natera's Earnings History.
Where is Natera's stock going? Where will Natera's stock price be in 2018?
4 analysts have issued 1 year price targets for Natera's shares. Their forecasts range from $12.00 to $16.00. On average, they expect Natera's share price to reach $14.33 in the next year. View Analyst Ratings for Natera.
Who are some of Natera's key competitors?
Some companies that are related to Natera include BioTelemetry (BEAT), U.S. Physical Therapy (USPH), Quality Systems (QSII), Kindred Healthcare (KND), Surgery Partners (SGRY), Almost Family (AFAM), Tabula Rasa HealthCare (TRHC), American Renal Associates (ARA), RadNet (RDNT), Triple-S Management (GTS), Hanger (HNGR), Civitas Solutions (CIVI), Addus Homecare (ADUS), Community Health Systems (CYH), Computer Programs & Systems (CPSI), InVitae (NVTA), Capital Senior Living (CSU) and NantHealth (NH).
Who are Natera's key executives?
Natera's management team includes the folowing people:
- Matthew Rabinowitz Ph.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder (Age 44)
- Jonathan Sheena, Co-Founder, Chief Technology Officer, Director (Age 44)
- Michael Burkes Brophy, Chief Financial Officer (Age 37)
- Roelof Frederick Botha, Lead Independent Director (Age 43)
- Todd C. Cozzens, Independent Director (Age 61)
- Edward C. Driscoll Jr. Ph.D., Independent Director (Age 64)
- James I. Healy M.D. Ph.D., Independent Director (Age 52)
- Gail Boxer Marcus, Independent Director (Age 60)
When did Natera IPO?
(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Has Natera been receiving favorable news coverage?
Media coverage about NTRA stock has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Natera earned a media sentiment score of 0.16 on Accern's scale. They also gave news stories about the medical research company an impact score of 46.29 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Natera's major shareholders?
Natera's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (4.34%), Macquarie Group Ltd. (2.78%), Driehaus Capital Management LLC (1.93%), Franklin Resources Inc. (1.80%), Bank of New York Mellon Corp (0.99%) and Geode Capital Management LLC (0.66%). Company insiders that own Natera stock include Herm Rosenman, Jonathan Sheena, Matthew Rabinowitz and Roelof Botha. View Institutional Ownership Trends for Natera.
Which institutional investors are selling Natera stock?
NTRA stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Franklin Resources Inc., Advisory Research Inc., Millennium Management LLC, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC, Jennison Associates LLC and Teachers Advisors LLC. Company insiders that have sold Natera company stock in the last year include Herm Rosenman and Jonathan Sheena. View Insider Buying and Selling for Natera.
Which institutional investors are buying Natera stock?
NTRA stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., First Manhattan Co., Deutsche Bank AG, Wells Fargo & Company MN, Schwab Charles Investment Management Inc., Jefferies Group LLC, MetLife Investment Advisors LLC and Geode Capital Management LLC. View Insider Buying and Selling for Natera.
How do I buy shares of Natera?
Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Natera's stock price today?
One share of NTRA stock can currently be purchased for approximately $9.52.
How big of a company is Natera?
Natera has a market capitalization of $538.61 million and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Natera employs 852 workers across the globe.
How can I contact Natera?
Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090.
MarketBeat Community Rating for Natera (NTRA)MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Natera (NASDAQ:NTRA) Earnings History and Estimates Chart
Natera (NASDAQ NTRA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.47)||($0.51)||$55.31 million||$56.66 million||View||N/A|
|8/8/2017||Q2 2017||($0.52)||($0.52)||$50.57 million||$53.60 million||View||Listen|
|5/9/2017||Q1 2017||($0.61)||($0.70)||$42.82 million||$46.90 million||View||Listen|
|3/7/2017||Q4 2016||($0.54)||($0.72)||$49.82 million||$49.30 million||View||Listen|
|11/9/2016||Q316||($0.55)||($0.50)||$48.14 million||$53.89 million||View||Listen|
|8/4/2016||Q216||($0.48)||($0.46)||$50.64 million||$52.00 million||View||Listen|
|5/10/2016||Q116||($0.46)||($0.17)||$48.17 million||$61.90 million||View||Listen|
|3/8/2016||Q415||($0.64)||($0.47)||$45.26 million||$52.90 million||View||Listen|
|11/12/2015||Q315||($0.46)||($0.39)||$43.08 million||$44.90 million||View||Listen|
|8/12/2015||Q2 2015||($0.45)||($2.98)||$42.69 million||$45.09 million||View||Listen|
Natera (NASDAQ:NTRA) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.87 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS
Dividend History for Natera (NASDAQ:NTRA)
No dividend announcements for this company have been tracked by MarketBeat.com
Natera (NASDAQ NTRA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.57%
Institutional Ownership Percentage: 67.60%
Natera (NASDAQ NTRA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/6/2017||Jonathan Sheena||Insider||Sell||120,000||$12.54||$1,504,800.00||533,208|| |
|4/5/2017||Herm Rosenman||Director||Sell||1,809||$8.55||$15,466.95||42,950|| |
|1/4/2017||Herm Rosenman||CFO||Sell||1,849||$11.87||$21,947.63||33,409|| |
|12/22/2016||Jonathan Sheena||Insider||Sell||16,213||$12.00||$194,556.00||645,972|| |
|12/20/2016||Jonathan Sheena||Insider||Sell||1,087||$12.00||$13,044.00||630,846|| |
|12/13/2016||Jonathan Sheena||Insider||Sell||2,700||$12.00||$32,400.00||632,459|| |
|12/6/2016||Herm Rosenman||CFO||Sell||1,828||$11.83||$21,625.24||30,237|| |
|12/5/2016||Matthew Rabinowitz||CEO||Sell||14,021||$12.02||$168,532.42||1,888,644|| |
|12/1/2016||Matthew Rabinowitz||CEO||Sell||56,072||$12.01||$673,424.72||1,942,572|| |
|11/28/2016||Matthew Rabinowitz||CEO||Sell||146,756||$12.50||$1,834,450.00||2,020,876|| |
|11/21/2016||Jonathan Sheena||Insider||Sell||32,505||$12.00||$390,060.00||630,165|| |
|11/3/2016||Herm Rosenman||CFO||Sell||1,852||$7.98||$14,778.96|| |
|10/6/2016||Herm Rosenman||CFO||Sell||1,773||$11.53||$20,442.69||22,051|| |
|10/5/2016||Jonathan Sheena||Insider||Sell||1,600||$12.00||$19,200.00||617,151|| |
|9/6/2016||Herm Rosenman||CFO||Sell||1,822||$10.21||$18,602.62||18,873|| |
|8/2/2016||Herm Rosenman||CFO||Sell||1,833||$12.98||$23,792.34||15,706|| |
|7/6/2016||Herm Rosenman||CFO||Sell||1,824||$12.10||$22,070.40||12,530|| |
|7/1/2016||Matthew Rabinowitz||CEO||Sell||104,892||$12.14||$1,273,388.88||2,167,354|| |
|6/19/2016||Jonathan Sheena||CTO||Sell||188,442||$11.94||$2,249,997.48||598,420|| |
|6/19/2016||Matthew Rabinowitz||CEO||Sell||732,831||$11.94||$8,750,002.14||2,876,595|| |
|6/19/2016||Roelof Botha||Director||Buy||837,521||$11.94||$10,000,000.74|| |
|6/2/2016||Herm Rosenman||CFO||Sell||1,806||$12.04||$21,744.24||9,336|| |
|2/1/2016||Jonathan Sheena||CTO||Sell||10,000||$8.03||$80,300.00||615,551|| |
|1/5/2016||Matthew Rabinowitz||CEO||Sell||54,683||$10.37||$567,062.71||2,762,777|| |
|1/4/2016||Jonathan Sheena||CTO||Sell||25,000||$10.06||$251,500.00||622,551|| |
|12/31/2015||Matthew Rabinowitz||CEO||Sell||111,513||$10.83||$1,207,685.79||2,817,460|| |
|12/29/2015||Jonathan Sheena||CTO||Sell||50,000||$10.44||$522,000.00||640,051|| |
|12/29/2015||Matthew Rabinowitz||CEO||Sell||83,804||$10.62||$889,998.48||2,928,973|| |
|7/8/2015||James Healy||Director||Buy||350,000||$18.00||$6,300,000.00|| |
|7/2/2015||James Healy||Director||Buy||400,000||$22.81||$9,124,000.00|| |
Natera (NASDAQ NTRA) News Headlines
|BidaskClub Downgrades Natera (NTRA) to Strong Sell|
www.americanbankingnews.com - March 24 at 8:23 PM
|Contrasting Davita (DVA) and Natera (NTRA)|
www.americanbankingnews.com - March 23 at 5:16 AM
|Natera Inc (NTRA) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - March 21 at 11:27 AM
|Natera (NTRA) and Its Competitors Financial Survey|
www.americanbankingnews.com - March 18 at 1:20 PM
|Edited Transcript of NTRA earnings conference call or presentation 13-Mar-18 9:00pm GMT|
finance.yahoo.com - March 18 at 9:32 AM
|Natera's (NTRA) CEO Matthew Rabinowitz on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - March 14 at 10:41 AM
|Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results - PR Newswire (press release)|
www.prnewswire.com - March 14 at 10:41 AM
|3 Stocks to Watch on Wednesday: Caleres Inc (CAL), Everi Holdings Inc (EVRI) and Natera Inc (NTRA) - Investorplace.com|
investorplace.com - March 14 at 10:41 AM
|3 Stocks to Watch on Wednesday: Caleres Inc (CAL), Everi Holdings Inc (EVRI) and Natera Inc (NTRA)|
investorplace.com - March 14 at 8:00 AM
|Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results|
finance.yahoo.com - March 13 at 6:12 PM
|Natera settles U.S. billing probe over prenatal gene tests for $11.4 mln|
www.reuters.com - March 13 at 9:57 AM
|QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform|
www.zacks.com - March 13 at 9:57 AM
|QIAGEN and Natera Partner to Develop Cutting-Edge Genetic Testing Assays for Use on QIAGEN’s GeneReader NGS System|
finance.yahoo.com - March 12 at 5:22 PM
|Natera (NTRA) to Release Quarterly Earnings on Tuesday|
www.americanbankingnews.com - March 8 at 8:16 PM
|Natera Inc. Announces Fourth Quarter and Fiscal 2017 Earnings Conference Call|
www.prnewswire.com - March 7 at 8:19 PM
|Natera Inc (NTRA) Expected to Post Earnings of -$0.43 Per Share|
www.americanbankingnews.com - March 6 at 5:08 PM
|Natera's Genetic Tests Now Fully Integrated into Yale New Haven Health's Epic EMR System|
finance.yahoo.com - March 5 at 4:53 PM
|Natera Inc (NTRA) Stake Boosted by Citadel Advisors LLC|
www.americanbankingnews.com - March 5 at 5:42 AM
|Natera Inc (NTRA) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - February 24 at 2:50 PM
|$56.83 Million in Sales Expected for Natera Inc (NTRA) This Quarter|
www.americanbankingnews.com - February 20 at 1:04 PM
| Analysts Expect Natera Inc (NTRA) Will Announce Earnings of -$0.43 Per Share|
www.americanbankingnews.com - February 18 at 1:10 AM
|Zacks: Brokerages Anticipate Natera Inc (NTRA) Will Post Quarterly Sales of $56.83 Million|
www.americanbankingnews.com - February 3 at 9:50 AM
|-$0.43 EPS Expected for Natera Inc (NTRA) This Quarter|
www.americanbankingnews.com - February 1 at 1:10 AM
|Natera Inc (NTRA) Given Consensus Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - January 30 at 1:52 PM
|Natera To Feature Expanded Panorama® Non-Invasive Prenatal Test, Now Validated for Twin Pregnancies, at SMFM Annual Meeting|
finance.yahoo.com - January 30 at 9:26 AM
|Natera (NTRA) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - January 20 at 9:10 AM
| Analysts Expect Natera Inc (NTRA) to Post -$0.43 Earnings Per Share|
www.americanbankingnews.com - January 15 at 3:30 AM
|Natera (NTRA) Upgraded to "Hold" by Zacks Investment Research|
www.americanbankingnews.com - January 10 at 6:44 AM
|Natera To Webcast Live Presentation at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018|
finance.yahoo.com - January 8 at 9:43 AM
|Natera Inc (NTRA) Expected to Post Quarterly Sales of $56.83 Million|
www.americanbankingnews.com - December 31 at 10:54 AM
|ETFs with exposure to Natera, Inc. : December 25, 2017|
finance.yahoo.com - December 25 at 6:58 PM
|Natera (NTRA) Earns "Buy" Rating from Cowen|
www.americanbankingnews.com - December 21 at 11:22 AM
|$56.53 Million in Sales Expected for Natera, Inc. (NTRA) This Quarter|
www.americanbankingnews.com - December 14 at 6:28 PM
|ETFs with exposure to Natera, Inc. : December 13, 2017|
finance.yahoo.com - December 13 at 5:22 PM
|Natera, Inc. (NTRA) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - December 11 at 1:58 PM
|ETFs with exposure to Natera, Inc. : December 1, 2017|
finance.yahoo.com - December 1 at 5:00 PM
|Natera, Inc. :NTRA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017|
finance.yahoo.com - November 30 at 10:07 AM
|Natera, Inc. (NTRA) Expected to Announce Quarterly Sales of $56.53 Million|
www.americanbankingnews.com - November 26 at 12:12 PM
|Zacks Investment Research Downgrades Natera, Inc. (NTRA) to Sell|
www.americanbankingnews.com - November 25 at 8:10 PM
|Head to Head Analysis: Natera (NTRA) & IRIS International (IRIS)|
www.americanbankingnews.com - November 17 at 1:42 PM
|Natera, Inc. (NTRA) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - November 16 at 11:54 AM
|Natera's (NTRA) Buy Rating Reiterated at Canaccord Genuity|
www.americanbankingnews.com - November 14 at 8:28 PM
|Natera, Inc. (NTRA) Announces Quarterly Earnings Results|
www.americanbankingnews.com - November 9 at 10:52 PM
|Natera, Inc. to Host Earnings Call|
finance.yahoo.com - November 9 at 9:38 AM
|Natera Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 9 at 9:38 AM
|Natera reports 3Q loss|
finance.yahoo.com - November 9 at 9:38 AM
|Edited Transcript of NTRA earnings conference call or presentation 8-Nov-17 9:30pm GMT|
finance.yahoo.com - November 9 at 9:38 AM
|IRIS International (IRIS) and Natera (NTRA) Head to Head Review|
www.americanbankingnews.com - November 7 at 11:00 AM
|Natera Selected for Circulating Tumor DNA Study in Colorectal Cancer|
finance.yahoo.com - November 7 at 7:57 AM
|ETFs with exposure to Natera, Inc. : November 6, 2017|
finance.yahoo.com - November 7 at 7:57 AM
Natera (NASDAQ:NTRA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Natera (NASDAQ:NTRA) Income Statement, Balance Sheet and Cash Flow Statement
Natera (NASDAQ NTRA) Stock Chart for Saturday, March, 24, 2018